MedTrace Logo

Study to Evaluate JCXH-211 as Monotherapy in Patients With Malignant Solid Tumors

NCT05727839 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2026-03-24

No results posted yet for this study

Summary

: A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability and Efficacy of JCXH-211 Intratumoral Injection in Patients with Malignant Solid Tumors

Conditions

  • Cutaneous Tumor
  • Malignant Solid Tumor

Interventions

DRUG

JCXH-211 Injection

JCXH-211 administered once every 28 days or 14days

Sponsors & Collaborators

  • Immorna Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Xu ruihua, President · Sun Yat-Sen University Cancer Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-24
Primary Completion
2024-09-30
Completion
2024-09-30

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05727839 on ClinicalTrials.gov